Duvelisib (Copiktra) approved in EU for treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL)

Duvelisib, an oral, dual inhibitor of phosphoinositide 3-kinases (PI3K-delta and gamma) is approved as monotherapy for treatment of CLL in patients, who have received ≥2 prior therapies and for treatment of FL that is refractory to ≥2 prior systemic therapies.

Source:

Biospace Inc.